Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DCFPyL PET/CT in Prostate Cancer
NCT03824275Phase 3Active, not recruiting
- Sponsor
- Columbia University
- Start
- Feb 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of piflufolastat f 18 in prostate cancer (PCa), sponsored by Columbia University. Primary endpoint: Positive Predictive Value at 3.5 years. Started Feb 2019; status: active, not recruiting.
02
Drugs
piflufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03824275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824275.